Fig. 5From: Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysisMeta-analysis of the global impression (very much/much better) at 2 h after therapy with lasmiditan compared with placebo. The diamond indicates the estimated relative risk with 95% confidence interval for the pooled patients. M-H, Mantel-Haenszel; CI, confidence intervalBack to article page